Replimune Group, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended December 31, 2020 (fiscal third quarter); filed February 4, 2021. Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies. It had no approved products and generated no product revenue.
Financial performance and position
Amounts below are in millions of dollars except per-share data. The filing reports no product revenue; therefore, revenue-based margins are not meaningful.
| Metric | Quarter ended Dec. 31, 2020 | Quarter ended Dec. 31, 2019 | Nine months ended Dec. 31, 2020 | Nine months ended Dec. 31, 2019 |
|---|---|---|---|---|
| Research and development expense | $14.3 | $11.9 | $40.5 | $27.6 |
| General and administrative expense | $6.0 | $4.7 | $17.2 | $12.2 |
| Total operating expenses / operating loss | $20.3 | $16.7 | $57.8 | $39.8 |
| Net loss | $21.8 | $16.2 | $59.4 | $36.8 |
| Basic and diluted net loss per share | $0.44 | $0.46 | $1.34 | $1.13 |
| Cash used in operating activities | Not separately presented for quarter | $45.3 | $49.3 | |
| Cash and cash equivalents plus short-term investments, Dec. 31, 2020 | $493.3 |
- Cash and cash equivalents were $324.5 million and short-term investments were $168.8 million at December 31, 2020. Total current assets were $499.4 million; total liabilities were $43.0 million.
- Cash, cash equivalents and restricted cash increased by $265.0 million over the nine months. Investing activities used $62.5 million and financing activities provided $371.7 million.
- The company repaid its $10.0 million Hercules term loan on December 15, 2020, paying $10.8 million in principal, interest and fees, and recorded a $0.9 million extinguishment loss. No term-loan principal remained outstanding at quarter-end. Finance and operating lease liabilities totaled $33.4 million.
- Equity financing was the main source of liquidity: the October 2020 offering generated approximately $270.0 million net, and the June 2020 offering generated approximately $107.8 million net. Shares outstanding were 46.4 million at December 31; pre-funded warrants for 5.3 million shares remained unexercised.
Changes versus the prior comparable period
- Quarterly operating expenses rose $3.6 million year over year and quarterly net loss increased $5.6 million. For the nine-month period, operating expenses rose $18.0 million and net loss increased $22.5 million.
- Higher R&D spending primarily reflected RP1 clinical-trial and manufacturing-facility costs, continued RP2/RP3 development, and increased personnel. Higher G&A reflected staffing, facility costs, insurance and professional fees.
- Nine-month operating cash use declined to $45.3 million from $49.3 million, while financing cash inflows increased substantially following the 2020 public offerings.
Outlook, developments and risks
- Management estimated that December 31 cash and investments would fund planned operations into the second half of 2024; the financial-statement notes separately state the funds should cover at least 12 months from issuance. Management cautions that assumptions may prove wrong and resources could be used sooner. No product-sales revenue or profitability guidance was provided; losses and expenses are expected to increase as programs advance.
- RP1: the company was enrolling a randomized Phase 2 CSCC trial with Regeneron’s cemiplimab, with primary readout expected in 2022. The transplant-recipient CSCC study had been delayed by COVID-19; first dosing was expected in early 2021, with initial data expected in the second half of 2021. A 125-patient anti-PD-1-failed melanoma cohort with BMS’s nivolumab was enrolling, with primary readout expected in 2022.
- RP2: combination enrollment with nivolumab was underway; initial combination data were expected in mid-2021. RP3: the first patient was dosed in a Phase 1 trial in December 2020, with initial data expected in the second half of 2021. These are management expectations, not assurances.
- COVID-19 had slowed enrollment in certain trials, particularly among highly immunocompromised transplant recipients. Further trial, supplier, manufacturing and operational disruptions remained possible.
- Replimune reported that disclosure controls and procedures were not effective as of December 31, 2020 because of previously identified material weaknesses, including insufficient accounting personnel and inadequate formal controls for complex transactions. Remediation and testing continued; management said the weaknesses were not yet fully remediated. Management nevertheless concluded the filed financial statements fairly presented the company’s position and results in all material respects.
- Key risks include clinical and regulatory failure or delay, the need for future capital and potential dilution, dependence on collaborators and third-party suppliers, execution and validation of in-house manufacturing, competition, intellectual-property challenges, and continuing COVID-19 effects. The company reported no material litigation and no off-balance-sheet arrangements.
Important facts for investors to verify
- Whether trial enrollment and anticipated data-readout timelines—especially RP1 CSCC and melanoma—remain on track.
- Whether the stated cash runway into the second half of 2024 remains supportable as clinical, staffing and manufacturing costs grow.
- Whether internal-control material weaknesses are remediated and controls operate effectively after testing.
- The status and potential dilution from outstanding pre-funded warrants, stock options and any future equity or ATM issuance.
- Whether COVID-19, manufacturing-facility validation, or reliance on BMS, Regeneron and contract manufacturers creates further delays or costs.